Table 1.
Patient and Disease Characteristics
| All Patients | Value or No. (%) | |||
|---|---|---|---|---|
| Characteristic | All Patients (n=32) |
Standard RT Dose (≥ 30Gy; n=21) | Lower RT Dose (≤ 24 Gy; n=11) |
P Value |
| Age, years, median (range) | 58 (32–88) | 58 (32–88) | 61 (35–72) | |
| Female | 13 (41%) | 9 (43%) | 4 (36%) | 1.00 |
| Disease stage | ||||
| I | 25 (78%) | 16 (76%) | 9 (82%) | .039 |
| II | 5 (16%) | 5 (24%) | 0 | |
| III | 0 | 0 | 0 | |
| IV | 2 (6%) | 0 | 2 (18%) | |
| B symptoms | ||||
| Yes | 2 (6%) | 1 (5%) | 1 (9%) | 0.577 |
| No | 30 (94%) | 20 (95%) | 10 (91%) | |
| MALT-IPI | ||||
| 0 | 28 (88%) | 19 (90%) | 9 (82%) | 0.281 |
| 1 | 3 (9%) | 1 (5%) | 2 (18%) | |
| Unknown | 1 (3%) | 1 (5%) | 0 | |
| Autoimmune disease | ||||
| Yes | 3 (9%) | 3 (14%) | 0 | 0.268 |
| No | 32 (89%) | 18 (86%) | 11 (100%) | |
| H. pylori infection | ||||
| Yes | 7 (22%) | 7 (33%) | 0 | 0.035 |
| No | 25 (78%) | 14 (67%) | 11 (100%) | |
| Large cell component | ||||
| Yes | 4 (13%) | 3 (14%) | 1 (9%) | 0.573 |
| No | 28 (88%) | 18 (86%) | 10 (91%) | |
| Location of dominant lesion | ||||
| Proximal 1/3 | 7 (22%) | 5 (24%) | 2 (18%) | 0.930 |
| Middle 1/3 | 17 (53%) | 11 (52%) | 6 (54%) | |
| Distal 1/3 | 8 (25%) | 5 (24%) | 3 (27%) | |
| Multifocal | ||||
| Yes | 11 (31%) | 8 (38%) | 1 (9%) | 0.090 |
| No | 25 (69%) | 13 (62%) | 10 (91%) | |
| Stomach thickening on CT | ||||
| Yes | 8 (75%) | 7 (33%) | 1 (9%) | 0.141 |
| No | 24 (75%) | 14 (67%) | 10 (91%) | |
| PET-CT performed | ||||
| Yes | 25 (78%) | 16 (76%) | 9 (82%) | 0.544 |
| No | 7 (22%) | 5 (24%) | 2 (18%) | |
| Stomach activity on PET? * | ||||
| Yes | 10 (40%) | 9 (56%) | 1 (11%) | .034 |
| No | 15 (60%) | 7 (44%) | 8 (91%) | |
Abbreviations: RT, Radiation therapy; MALT-IPI, mucosa associated lymphoid tissue international prognostic index; CT, computed tomography; PET-CT, Positron emission tomography–computed tomography;
*
Percentages for stomach activity on pet calculated based on patients that had PET-CT imaging performed